<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422175</url>
  </required_header>
  <id_info>
    <org_study_id>CBAF312A2101</org_study_id>
    <nct_id>NCT00422175</nct_id>
  </id_info>
  <brief_title>Single Dose Study to Assess the Safety, Tolerability, Concentration in Body and Effect of BAF312</brief_title>
  <official_title>A First-in-Human Study for BAF312: A Two Parts, Single Center, Randomized, Double-Blind, Placebo-Controlled Ascending Single Dose Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral BAF312 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and effect of oral BAF312 on&#xD;
      bodily functions as well as the body's absorption, distribution, metabolism, and excretion of&#xD;
      BAF312 in healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety, tolerability, and pharmacokinetic profile</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte counts and lymphocyte recovery period</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac rate and rhythm</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
  </secondary_outcome>
  <enrollment>63</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAF 312</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female subjects, 18 to 55 years of age included, and in good health&#xD;
&#xD;
          -  Female subjects must be either surgically sterilized at least 6 months prior to study&#xD;
             participation or post-menopausal (no regular menstrual bleeding for at least 1 years)&#xD;
&#xD;
          -  Female subjects test are required to have a negative result for a pregnancy test, not&#xD;
             be lactating/breast feeding, and must either:&#xD;
&#xD;
          -  Body mass index (BMI) must be within the range of 18 to 30 Kg/m2. Subjects must weigh&#xD;
             at least 50 kg to participate in this study.&#xD;
&#xD;
          -  Able to communicate with the investigator, to understand and comply with the&#xD;
             requirements of the study&#xD;
&#xD;
          -  Understand and sign the written informed consent firm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Subjects who received live vaccine 4 weeks prior to dosing.&#xD;
&#xD;
          -  Use of any prescription drugs four weeks prior dosing, or over-the-counter (OTC)&#xD;
             medication (vitamins, herbal supplements, dietary supplements) within two weeks prior&#xD;
             to dosing. Acetaminophen is acceptable&#xD;
&#xD;
          -  Participation in any clinical investigation within 4 weeks prior to dosing or longer&#xD;
             if required by local regulations, and for any other limitation of participation based&#xD;
             on local regulations.&#xD;
&#xD;
          -  Donation or loss of 400 ml or more of blood within 8 weeks prior to first dosing, or&#xD;
             longer if required by local regulation.&#xD;
&#xD;
          -  Significant illness within two weeks prior to dosing.&#xD;
&#xD;
          -  A past personal or close family medical history of clinically significant cardiac&#xD;
             abnormalities&#xD;
&#xD;
          -  History of Acute or chronic bronchospastic disease (including asthma and chronic&#xD;
             obstructive pulmonary disease) Clinically significant drug allergy or history of&#xD;
             atopic allergy (asthma, urticaria, eczematous dermatitis) Known hypersensitivity or&#xD;
             severe adverse event to darifenacin or similar drugs Any surgical or medical condition&#xD;
             which might significantly alter the absorption, distribution, metabolism or excretion&#xD;
             of drugs or which may jeopardize participation in the study Immunodeficiency diseases,&#xD;
             including a positive HIV (ELISA and Western blot) test result Positive Hepatitis B&#xD;
             surface antigen (HBsAg) or Hepatitis C test result. Drug or alcohol abuse&#xD;
&#xD;
        Additional protocol defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigative site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>January 11, 2007</study_first_submitted>
  <study_first_submitted_qc>January 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2007</study_first_posted>
  <last_update_submitted>November 28, 2007</last_update_submitted>
  <last_update_submitted_qc>November 28, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2007</last_update_posted>
  <keyword>Safety, tolerability, pharmacokinetics, pharmacodynamics, oral, BAF312, healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Siponimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

